4-[2-Amino-1-(2,4-difluoro-phenyl)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester | 444892-56-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-[2-Amino-1-(2,4-difluoro-phenyl)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-[2-amino-1-(2,4-difluorophenyl)ethyl]piperazine-1-carboxylate
• CAS: 444892-56-2
• 化学式: C₁₇H₂₅F₂N₃O₂
• 分子量: 341.401
• InChiKey: COPLXHBFUMSAEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  58.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[2-Amino-1-(2,4-difluoro-phenyl)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester 、 溴乙烷 在 potassium carbonate 作用下， 生成 Tert-butyl 4-[2-(diethylamino)-1-(2,4-difluorophenyl)ethyl]piperazine-1-carboxylate
  参考文献：
  名称：

  Privileged structure based ligands for melanocortin receptors—Substituted benzylic piperazine derivatives

  摘要：

  Replacement of the aryl piperazine moiety in compound I with a variety of substituted benzylic piperazines (6) yields compounds that afford melanocortin receptor 4 (MCR4) activity. Analogs with ortho substitution on the aromatic ring afforded the highest affinity. Resolution of the stereocenter of the benzylic piperazine based privileged structure revealed that the R-enantiomer was more active. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.018
• 作为产物：
  描述：

  2,4-二氟苯甲醛 在 lithium aluminium tetrahydride 、 zinc(II) iodide 作用下， 生成 4-[2-Amino-1-(2,4-difluoro-phenyl)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Privileged structure based ligands for melanocortin receptors—Substituted benzylic piperazine derivatives

  摘要：

  Replacement of the aryl piperazine moiety in compound I with a variety of substituted benzylic piperazines (6) yields compounds that afford melanocortin receptor 4 (MCR4) activity. Analogs with ortho substitution on the aromatic ring afforded the highest affinity. Resolution of the stereocenter of the benzylic piperazine based privileged structure revealed that the R-enantiomer was more active. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.018

文献信息

• Melanocortin receptor agonists
  申请人：——

  公开号：US20040116699A1

  公开（公告）日：2004-06-17

  The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction 1

  本发明涉及公式I的黑色素细胞激素受体激动剂，用于治疗肥胖症、糖尿病以及男性和/或女性性功能障碍。
• US7169777B2
  申请人：——

  公开号：US7169777B2

  公开（公告）日：2007-01-30
• Privileged structure based ligands for melanocortin receptors—Substituted benzylic piperazine derivatives
  作者：Matthew J. Fisher、Ryan T. Backer、Iván Collado、Óscar de Frutos、Saba Husain、Hansen M. Hsiung、Steve L. Kuklish、Ana I. Mateo、Jeffrey T. Mullaney、Paul L. Ornstein、Cristina García Paredes、Thomas P. O’Brian、Timothy I. Richardson、Jikesh Shah、John M. Zgombick、Karin Briner

  DOI：10.1016/j.bmcl.2005.08.018

  日期：2005.11

  Replacement of the aryl piperazine moiety in compound I with a variety of substituted benzylic piperazines (6) yields compounds that afford melanocortin receptor 4 (MCR4) activity. Analogs with ortho substitution on the aromatic ring afforded the highest affinity. Resolution of the stereocenter of the benzylic piperazine based privileged structure revealed that the R-enantiomer was more active. (c) 2005 Elsevier Ltd. All rights reserved.